1088993-91-2

Upstream product

• 1088993-89-8 (2R,5R)-benzyl 5-(hydroxymethyl)-2-methyl-piperidine-1-carboxylate 
• 51173-05-8 5-fluoropyridin-2-ol 
• 1427597-05-4 C₁₅H₂₀BrNO₂ 
• 1427597-09-8 C₁₅H₂₀INO₂ 
• 1427597-14-5 C₁₆H₂₃NO₅S 
• 1427597-15-6 C₂₂H₂₇NO₅S 
• 278789-37-0 (6-methyl-piperidin-3-yl)methanol 

Downstream Products

• 1088994-37-9 2-(((3R,6R)-1-(2-bromo-5-vinyl-benzoyl)-6-methyl-piperidin-3-yl)methoxy)-5-fluoro-pyridine 
• 1088994-39-1 4-bromo-3-(((2R,5R)-5-(((5-fluoropyridin-2-yl)oxy)methyl)-2-methylpiperidin-1-yl)carbonyl)benzaldehyde 
• 1088993-96-7 5-fluoro-2-(((3R,6R)-1-(2-iodo-5-methyl-benzoyl)-6-methyl-piperidin-3-yl)methoxy)pyridine 
• 1088994-41-5 (4-bromo-3-(((2R,5R)-5-(((5-fluoro-pyridin-2-yl)oxy)methyl)-2-methyl-piperidin-1-yl)carbonyl)phenyl)-methanol 
• 1088994-28-8 2-(((3R,6R)-1-(5-bromo-2-iodobenzoyl)-6-methylpiperidin-3-yl)methoxy)-5-fluoro-pyridine 
• 1088994-34-6 2-(((3R,6R)-1-(2-bromo-5-iodo-benzoyl)-6-methyl-piperidin-3-yl)methoxy)-5-fluoro-pyridine 
• 1088991-70-1 5-fluoro-2-(((3R,6R)-6-methyl-1-(5-methyl-2-(2H-1,2,3-triazol-2-yl)-benzoyl)-piperidin-3-yl)-methoxy)-pyridine 
• 1088994-24-4 2-((3R,6R)-1-(5-bromo-2-(2H-1,2,3-triazol-2-ylbenzoyl)-6-methyl-piperidin-3-yl)methoxy)-5-fluoro-pyridine 
• 1088991-71-2 2-(2-(((2R,5R)-5-(((5-fluoropyridin-2-yl)oxy)methyl)-2-methyl-piperidin-1-yl)carbonyl)-4-methylphenyl)pyrazine 
• 1088994-43-7 4-bromo-3-(((2R,5R)-5-(((5-fluoropyridin-2-yl)oxy)methyl)-2-methyl-piperidin-1-yl)carbonyl)benzyl acetate 
• 1088994-30-2 2-(4-bromo-2-(((2R,5R)-5-(((5-fluoropyridin-2-yl)oxy)methyl)-2-methyl-piperidin-1-yl)carbonyl)phenyl)pyrimidine 
• 1088991-75-6 C₂₂H₂₄FN₅O₃ 
• 1088994-26-6 methyl 3-[(2R,5R)-5-(5-fluoro-pyridin-2-yloxymethyl)-2-methyl-piperidine-1-carbonyl]-4-[1,2,3]triazol-2-yl-benzoate 
• 1088991-74-5 3-[(2R,5R)-5-(5-fluoro-pyridin-2-yloxymethyl)-2-methyl-piperidine-1-carbonyl]-4-[1,2,3]triazol-2-yl-benzoic acid 

Relevant academic research and scientific papers

Convergent kilogram-scale synthesis of dual orexin receptor antagonist

MK-6096 is an orexin receptor antagonist in clinical trials for the treatment of insomnia. Herein we describe its first kilogram-scale synthesis. Chirality on the α-methylpiperidine core was introduced in a biocatalytic transamination using a three-enzyme system with excellent enantioselectivity (>99% ee). Low diastereoselectivity of the lactam reduction was overcome by development of a camphor sulfonic acid salt formation and dr upgrade. A chemoselective O-alkylation with 5-fluoro-2-hydroxypyridine was optimized and developed. Overall, 1.2 kg of MK-6069 was prepared in nine steps and 13% overall yield.

PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS

The present invention is. directed to pyridyl piperidine compounds of formula (I) which are antagonists of orexin receptors, and which are useful' in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.